TACE and MWA Combination Therapy for Early Stage HCC
This study will compare the results of transarterial chemoembolization (TACE) and microwave ablation (MWA) combination therapy with MWA monotherapy for the treatment of early (stages 0 and A) hepatocellular carcinoma (HCC). The primary aim is to compare 2 year intrahepatic disease-free survival. Secondary aims are: 1) to determine the clinical feasibility of TACE + MWA in HCC patients with a small tumor burden and 2) to determine the effect of TACE on radiographic tumor characteristics.
Who may be Eligible
Male or female patients aged 18 to 75 years with a primary diagnosis of hepatocellular carcinoma.